Kancera unites industrial and clinical expertise. The goal is to develop a new generation of cancer drugs to combat those properties that currently cause tumors to recur, often in a more malignant and resistant form.
Kancera has two pharmaceutical projects in its existing product development portfolio, one for leukaemia and one for solid tumors. The development of the new drug types is being carried out as a close collaboration between clinical and industrial expertise. This creates the opportunity to make the risky development of new methods of treatment more reliable.
Kancera was founded in the spring of 2010. On February 25, 2011, the share was linked into the NASDAQ OMX First North.